CONCORD

Concord Drugs Ltd.

BSE: 538965

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

71.21-2.2 (-2.98%)

7 Aug, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

Score not available

Value Score

Score not available

Price Momentum Score

Score not available

QVM Score

Score not available

Key Metrics

Market Cap

71.21

P/E (TTM)

67.50

P/B

1.47

P/S (TTM)

0.90

EV/EBITDA

18.79

CAPE (5Y)

76.73

ROE (TTM)

2.55

ROCE (TTM)

5.42

ROA (TTM)

1.51

Avg 3Y ROE

1.66

Earnings 3Y CAGR

-3.53

Sales 3Y CAGR

14.77

Sales 5Y CAGR

8.92

Debt/Equity

0.30

Consensus TP

Strong Buy %

Promoter Holding

45.08

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Concord Drugs Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Not enough talking points with positive stance

Negative

Expensive and at a premium to industry median P/E

PE TTM of 67.5 indicates that the stock is expensive on a standalone basis and is at a 120.66% premium to industry median P/E

What is P/E Ratio?

Median: 30.59

Value 67.5

0.33286.35

Low dividend yield

The company has a low dividend yield of 0.0%

What is Dividend yield?

Neutral

Not enough talking points with neutral stance

Financial Snapshot

See detailed analysis

Multi-year trends for Concord Drugs Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Concord Drugs Ltd. Shareholding Pattern

Quarterly breakdown of Concord Drugs Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	42.78	42.78	42.78	42.78	44.38	44.38	49.00	49.00	49.00	49.00	49.00	49.00	52.13	52.13	52.13	55.41	55.41	55.41	54.39	54.39	54.39	54.39	54.39	54.39	54.39	45.08
Indian Promoter	42.78	42.78	42.78	42.78	44.38	44.38	49.00	49.00	49.00	49.00	49.00	49.00	52.13	52.13	52.13	55.41	55.41	55.41	54.39	54.39	54.39	54.39	54.39	54.39	54.39	45.08
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	0.04	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Mutual Funds / UTI	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FI/Bank/Insurance	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Non-Institution	57.18	57.22	57.22	57.22	55.62	55.62	51.00	51.00	51.00	51.00	51.00	51.00	47.87	47.87	47.87	44.59	44.59	44.59	45.61	45.61	45.61	45.61	45.61	45.61	45.61	54.92
Bodies Corporate	0.21	0.16	0.09	0.09	0.09	0.14	0.22	0.11	0.01	0.02	0.04	0.02	0.02	0.04	0.08	0.18	0.12	0.09	0.08	0.08	0.08	0.02	0.43	0.42	0.80	0.32
Others (incl. Retail) No. of shareholders	56.97 1,954	57.06 2,020	57.13 2,072	57.13 2,115	55.53 2,166	55.48 2,673	50.78 2,817	50.89 3,063	50.99 3,041	50.98 3,029	50.96 3,180	50.98 3,313	47.85 3,197	47.83 3,190	47.79 3,948	44.41 4,020	44.47 4,723	44.50 4,743	45.53 5,062	45.53 5,062	45.53 5,242	45.59 5,179	45.18 4,709	45.19 4,587	44.81 4,452	54.60 4,587

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Concord Drugs Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
S.Manoj Kumar Reddy Promoter & Director	October-2023	Conversion of security (Acquisition) 30th Oct 2023	15.09 %	₹ 24.75	1.71 lac	₹ 42.36 lac
S.Nagi Reddy Promoter & Director	October-2023	Conversion of security (Acquisition) 30th Oct 2023	28.39 %	₹ 24.75	1.71 lac	₹ 42.36 lac
S.Manoj Kumar Reddy Promoter & Director	October-2023	Conversion of security (Acquisition) 14th Oct 2023	13.80 %	₹ 24.75	1.71 lac	₹ 42.36 lac
S.Nagi Reddy Promoter & Director	October-2023	Conversion of security (Acquisition) 14th Oct 2023	27.59 %	₹ 24.75	1.71 lac	₹ 42.36 lac
S. Manoj Reddy Promoter & Director	March-2023	Conversion of security (Acquisition) 29th Mar 2023	11.07 %	₹ 24.75	2.86 lac	₹ 70.75 lac
S. Nagi Reddy Promoter & Director	March-2023	Conversion of security (Acquisition) 29th Mar 2023	25.30 %	₹ 24.75	2.86 lac	₹ 70.75 lac
S. Nagi Reddy Promoter & Director	November-2021	Inter-se Transfer (Acquisition) 15th Nov 2021	21.58 %	₹ 0.00	3.98 lac	₹ 0.00
V. Ramasubba Reddy Promoter	November-2021	Inter-se Transfer (Disposal) 15th Nov 2021	4.55 %	₹ 0.00	3.98 lac	₹ 0.00
S. Koni Reddy Promoter & Director	September-2021	Market Purchase (Acquisition) 30th Sep 2021	11.15 %	₹ 27.18	25.00 k	₹ 6.79 lac
S. Nagi Reddy Promoter & Director	September-2021	Market Purchase (Acquisition) 24th Sep 2021	21.07 %	₹ 28.00	44.36 k	₹ 12.42 lac

No corporate action data available.

Company Profile

Overview of Concord Drugs Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Concord Drugs Limited is an India-based pharmaceutical company. The Companys principal activity is to manufacture licensed drugs based on the formulations approved. The Company is focused on developing drug delivery systems, including multiple unit pellet system (MUPS), sustained release, and modifi...

Key personnel

Ms. Namratha Nagla

Compliance Officer, Company Secretary

Mr. Seelam Nagi ReddyD

Executive Chairman of the Board, Managing Director

Mr. Seelam Koni ReddyD

Chief Financial Officer, Whole time Director

Mr. S. Manoj Kumar ReddyD

Additional Whole-Time Director

Mr. Satyam Reddy GopidiD

Additional Non-Executive Independent Director

Mr. S. Nagavenkata HareeshD

Additional Non-Executive Independent Director

Mr. K. Ramachandra ReddyD

Non-Executive Independent Director

Mrs. K. SumeelaD

Non-Executive Independent Director

Incorporated on

24 Apr 1995

Last Annual

31 Mar 2026

Last Interim

31 Mar 2026

No. of Employees

IPO date

23 Feb 2015

Free Float

67,66,612

Website

https://concorddrugs.in/

Phone no.

+914024036379

Address

SURVEY NO. 249, BRAHMANAPALLY, HAYATNAGAR, R.R.D, , 501511, India

Frequently Asked Questions

What is the current share price of Concord Drugs Ltd.?

The current share price of Concord Drugs Ltd. is ₹ 71.21 as of 7 Aug 2026.

What is the market capitalisation of Concord Drugs Ltd.?

The market capitalisation of Concord Drugs Ltd. stands at ₹ 71.21 Cr.

What is the PE ratio of Concord Drugs Ltd.?

The Price-to-Earnings (PE) ratio of Concord Drugs Ltd. is 67.50 as of the latest trailing twelve months data.

What is the ROE and ROCE of Concord Drugs Ltd.?

Concord Drugs Ltd. has a Return on Equity (ROE) of 2.55% and a Return on Capital Employed (ROCE) of 5.42% as per the latest financial reports.

What is the 52-week high and low of Concord Drugs Ltd.?

The 52-week high of Concord Drugs Ltd. is - and the 52-week low is -.

What is the dividend yield of Concord Drugs Ltd.?

The dividend yield of Concord Drugs Ltd. is 0.00% based on the current market price.

What is the FII and DII holding in Concord Drugs Ltd.?

Foreign Institutional Investors (FII) hold 0.00%, Domestic Institutional Investors (DII) hold 0.00% and retail/public investors hold 54.60% of Concord Drugs Ltd. shares.

What sector does Concord Drugs Ltd. belong to?

Concord Drugs Ltd. operates in the Healthcare sector.

What is the beta of Concord Drugs Ltd.?

The beta of Concord Drugs Ltd. is 0.38, indicating its price volatility relative to the broader market. Over the past 1 year, Concord Drugs Ltd. has delivered an absolute return of 27.16%.

What is the RSI of Concord Drugs Ltd.?

The 14-day Relative Strength Index (RSI) of Concord Drugs Ltd. is 47.46, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.

Concord Drugs Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Concord Drugs Ltd. Shareholding Pattern

Bulk, Block and Insider Trades

Company Profile

Frequently Asked Questions

Stock Analysis

Company Profile